longer-term-efficacy-and-safety-of-evinacumab-in-patients-with-refractory-hypercholesterolemia 2023-09-14T16:50:38.954Z c3e39a56-de18-4679-8db0-58f3a098c750 mas_evidence_types:Randomised%20controlled%20trials Primary research In 48 week open-label treatment period of phase 2 trial (n=96; LDL-C 3.77 mmol/L.), evinacumab (15mg/kg IV every 4 weeks) provided sustained reductions in LDL-C over time, with a mean reduction of 45.5% at week 72 from baseline. <p>Angiopoietinlike protein 3 (ANGPTL3) plays an important role in regulating lipoprotein metabolism via inhibition of lipoprotein lipase and endothelial lipase. Evinacumab is a monoclonal antibody that inhibits ANGPTL3, promoting remodeling of very low-density lipoprotein and leading to reduced LDL-C levels. It is licensed in UK as an adjunct to diet and other LDL-C lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia.</p> https://www.medicinesresources.nhs.uk/longer-term-efficacy-and-safety-of-evinacumab-in-patients-with-refractory-hypercholesterolemia.html https://jamanetwork.com/journals/jamacardiology/article-abstract/2809517 2023-09-13T00:00:00Z 2023-09-14T13:50:19.78Z